MARKET

BMRN

BMRN

BioMarin Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

77.77
-0.84
-1.07%
After Hours: 77.77 0 0.00% 16:57 05/07 EDT
OPEN
79.00
PREV CLOSE
78.61
HIGH
79.83
LOW
77.07
VOLUME
628.86K
TURNOVER
--
52 WEEK HIGH
131.95
52 WEEK LOW
71.35
MARKET CAP
14.21B
P/E (TTM)
-212.7188
1D
5D
1M
3M
1Y
5Y
Insider Trends: BioMarin Pharmaceuticals Insider Awarded Shares Uses Portion to Pay Taxes, Easing 90-Day Buy Trend
MT Newswires · 2d ago
Was The Smart Money Right About BioMarin (BMRN)?
In this article you are going to find out whether hedge funds think BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although the...
Insider Monkey · 3d ago
Enzyme Replacement Therapy Market Research Report: Size, Share, Opportunities, Challenges, Statistics, Restraints, Drivers with Key Player by 2021-2027
May 04, 2021 (Heraldkeepers) -- The Enzyme Replacement Therapy Market is segmented on the Basis of Therapeutic Conditions Type, Route of Administration Type,...
Heraldkeepers · 3d ago
Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market Size 2021 By Industry Share, Key Findings, Company Profiles, Growth Strategy, Developing Technologies, Demand, Investment Opportunities and Forecast by Regions till 2027
May 04, 2021 (The Expresswire) -- As per a new research report titled Global “Gaucher and Pompe Diseases Enzyme Replacement Therapy (ERT) Market” 2021 by...
The Express Wire · 3d ago
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in two upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at: https://investors.biomarin.com/. ...
PR Newswire · 4d ago
Estimating The Fair Value Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Simply Wall St. · 4d ago
BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision
Zacks.com · 04/30 13:58
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Biomarin Pharmaceutical Inc.
MT Newswires · 04/30 11:19
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BMRN. Analyze the recent business situations of BioMarin Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BMRN stock price target is 108.56 with a high estimate of 183.00 and a low estimate of 82.00.
EPS
Institutional Holdings
Institutions: 777
Institutional Holdings: 193.94M
% Owned: 106.13%
Shares Outstanding: 182.74M
TypeInstitutionsShares
Increased
188
11.90M
New
93
2.40M
Decreased
170
9.30M
Sold Out
53
1.87M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Chief Executive Officer/Director
Jean-Jacques Bienaime
Chief Financial Officer/Executive Vice President
Brian Mueller
Corporate Executive
Henry Fuchs
Executive Vice President/Chief Technology Officer
C. Greg Guyer
Executive Vice President/General Counsel/Secretary
G. Eric Davis
Executive Vice President
Jeff Ajer
Chief Accounting Officer/Vice President
Andrea Acosta
Chief Scientific Officer
Lon Cardon
Lead Director/Independent Director
Richard Meier
Director
Liz Anderson
Director
Maykin Ho
Independent Director
Elizabeth Anderson
Independent Director
Willard Dere
Independent Director
Michael Grey
Independent Director
Elaine Heron
Independent Director
Robert Hombach
Independent Director
V. Bryan Lawlis
Independent Director
Alan Lewis
Independent Director
David Pyott
Independent Director
Dennis Slamon
No Data
About BMRN
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Webull offers kinds of BioMarin Pharmaceutical Inc. stock information, including NASDAQ:BMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMRN stock methods without spending real money on the virtual paper trading platform.